MCID: SRS001
MIFTS: 51

Serous Cystadenocarcinoma malady

Categories: Cancer diseases

Aliases & Classifications for Serous Cystadenocarcinoma

Aliases & Descriptions for Serous Cystadenocarcinoma:

Name: Serous Cystadenocarcinoma 12 14
Cystadenocarcinoma, Serous 42 69
Serous Cystadenocarcinoma, Nos 12
Cystadenocarcinoma Serous 52
Serous Adenocarcinoma 12
Serous Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3114
MeSH 42 D018284
NCIt 47 C3778 C40101
SNOMED-CT 64 189685001 90725004
UMLS 69 C0206701

Summaries for Serous Cystadenocarcinoma

Disease Ontology : 12 A cystadenocarcinoma that derives from epithelial cells originating in glandular tissue forming serous lesions.

MalaCards based summary : Serous Cystadenocarcinoma, also known as cystadenocarcinoma, serous, is related to pancreatic serous cystadenocarcinoma and ovarian serous cystadenocarcinoma. An important gene associated with Serous Cystadenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Gene Expression and GPCR Pathway. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include ovary, pancreas and liver, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and hematopoietic system

Wikipedia : 71 Serous cystadenocarcinoma is a type of tumor in the cystadenocarcinoma... more...

Related Diseases for Serous Cystadenocarcinoma

Diseases related to Serous Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 96)
id Related Disease Score Top Affiliating Genes
1 pancreatic serous cystadenocarcinoma 12.2
2 ovarian serous cystadenocarcinoma 12.2
3 ovarian serous carcinoma 12.0
4 primary peritoneal carcinoma 11.7
5 papillary serous adenocarcinoma 11.0
6 cystadenocarcinoma 10.7
7 aortitis 10.2 PGR TP53
8 pericardium leiomyoma 10.2 PGR TP53
9 deafness, autosomal recessive 21 10.2 ESR2 PGR
10 reactive arthritis 10.2 ESR2 PGR TP53
11 fallopian tube carcinosarcoma 10.1 PGR TP53 VEGFA
12 plasmacytoma 10.1 BAX TP53 ZNF217
13 spondylolysis 10.1 ESR2 PGR VEGFA
14 progesterone-receptor negative breast cancer 10.1 AKT1 PGR TP53
15 his bundle tachycardia 10.1 BCL2 PGR TP53
16 spastic paraplegia 1 10.1 BCL2 TP53 VEGFA
17 pituitary stalk meningioma 10.1 ESR2 PGR TP53
18 kidney disease 10.1 BAX BCL2 TP53
19 breast ductal carcinoma 10.1 PGR TP53
20 adult neuronal ceroid lipofuscinosis 10.1 MMP2 PGR VEGFA
21 progesterone-receptor positive breast cancer 10.1 AKT1 PGR TP53
22 gestational choriocarcinoma 10.1 AKT1 TP53 VEGFA
23 cleft palate cardiac defect ectrodactyly 10.1 BCL2 TP53 VEGFA
24 pancreatitis 10.1
25 peritonitis 10.1
26 necrobiosis lipoidica 10.1 ESR2 PGR TP53
27 statin toxicity 10.1 BCL2 BIRC5 TP53
28 acute mountain sickness 10.1 CDKN1A TP53
29 prostatic adenoma 10.1 ESR2 PGR TP53 VEGFA
30 pearson syndrome 10.0 AKT1 TP53 VEGFA
31 adult medulloblastoma 10.0 AKT1 ESR2 TP53 VEGFA
32 lower lip cancer 10.0 AKT1 BIRC5 MMP2
33 inverted follicular keratosis 10.0 BIRC5 CDKN1A TP53
34 cervical serous adenocarcinoma 10.0 UBE4A USP2 ZNF217
35 breast mucinous cystadenocarcinoma 10.0 UBE4A USP2 ZNF217
36 pyloric antrum cancer 10.0 BAX BCL2 TP53 VEGFA
37 vaginal adenosarcoma 10.0 BCL2 BIRC5 PGR TP53
38 benign shuddering attacks 10.0 AKT1 TP53 VEGFA
39 nodular cutaneous amyloidosis 10.0 BIRC5 MMP2 TP53
40 plague 10.0 BAX CDKN1A TP53
41 vaginal endometrial stromal sarcoma 10.0 AKT1 MUC16 VEGFA
42 metagonimiasis 10.0 MMP2 PGR TP53 VEGFA
43 familial glucocorticoid deficiency 9.9 PGR TP53 VEGFA
44 glucose-6-phosphate translocase deficiency 9.9 AKT1 CDKN1A TP53 VEGFA
45 adult astrocytic tumour 9.9 AKT1 CDKN1A TP53 VEGFA
46 thoracic outlet syndrome 9.9 AKT1 BCL2 CDKN1A TP53
47 maxillary sinus cholesteatoma 9.9 CDKN1A MMP2 TP53
48 grade iii astrocytoma 9.9 AKT1 MMP2 TP53 VEGFA
49 pulmonary fibrosis and/or bone marrow failure, telomere-related, 1 9.9 MMP2 TP53 VEGFA
50 marginal zone b-cell lymphoma 9.9 BCL2 MMP2 TP53 VEGFA

Graphical network of the top 20 diseases related to Serous Cystadenocarcinoma:



Diseases related to Serous Cystadenocarcinoma

Symptoms & Phenotypes for Serous Cystadenocarcinoma

GenomeRNAi Phenotypes related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.7 BCL2 BIRC5 CDKN1A TP53 AKT1 BAX
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.7 BCL2 BIRC5 CDKN1A TP53 AKT1 BAX

MGI Mouse Phenotypes related to Serous Cystadenocarcinoma:

44 (show all 15)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.24 CDKN1A ESR2 MMP2 PGR TP53 USP2
2 cellular MP:0005384 10.22 TP53 USP2 VEGFA AKT1 BAX BCL2
3 homeostasis/metabolism MP:0005376 10.22 AKT1 BAX BCL2 BIRC5 CDKN1A ESR2
4 endocrine/exocrine gland MP:0005379 10.21 AKT1 BAX BCL2 BIRC5 CDKN1A ESR2
5 behavior/neurological MP:0005386 10.2 AKT1 BAX BCL2 CDKN1A ESR2 PGR
6 cardiovascular system MP:0005385 10.19 AKT1 BCL2 CDKN1A ESR2 MMP2 PGR
7 immune system MP:0005387 10.16 CDKN1A ESR2 MMP2 PGR TP53 VEGFA
8 muscle MP:0005369 10.02 AKT1 BAX BCL2 CDKN1A ESR2 MMP2
9 integument MP:0010771 9.98 AKT1 BCL2 CDKN1A ESR2 PGR TP53
10 neoplasm MP:0002006 9.97 ESR2 MMP2 PGR TP53 VEGFA AKT1
11 limbs/digits/tail MP:0005371 9.88 BAX CDKN1A ESR2 PGR TP53 VEGFA
12 reproductive system MP:0005389 9.81 AKT1 BAX BCL2 CDKN1A ESR2 PGR
13 renal/urinary system MP:0005367 9.8 BAX BCL2 CDKN1A ESR2 TP53 USP2
14 respiratory system MP:0005388 9.56 AKT1 BAX BCL2 CDKN1A ESR2 MMP2
15 skeleton MP:0005390 9.23 AKT1 BAX CDKN1A ESR2 MMP2 PGR

Drugs & Therapeutics for Serous Cystadenocarcinoma

Drugs for Serous Cystadenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 218)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
3
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
4
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
5
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
6
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
7
Epirubicin Approved Phase 3 56420-45-2 41867
8
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
9
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
10
Levoleucovorin Approved Phase 3,Phase 2,Phase 1 68538-85-2
11
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
12
Topotecan Approved, Investigational Phase 2, Phase 3, Phase 1 119413-54-6, 123948-87-8 60700
13
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
14
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
15
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
16
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
17
Gemcitabine Approved Phase 3,Phase 1,Phase 2 95058-81-4 60750
18
Olaparib Approved Phase 2, Phase 3,Phase 1 763113-22-0 23725625
19
Metformin Approved Phase 2, Phase 3,Phase 1 657-24-9 14219 4091
20
Succinylcholine Approved Phase 3,Phase 2,Phase 1 306-40-1 5314
21
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
22
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
23
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
24
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
25
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
26
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
27
Camptothecin Experimental Phase 3,Phase 2,Phase 1 7689-03-4
28
Cediranib Investigational Phase 2, Phase 3,Phase 1 288383-20-0 9933475
29
Maleic acid Experimental Phase 2, Phase 3,Phase 1 110-16-7 444266
30 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
31 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
32 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
33 Antimitotic Agents Phase 3,Phase 2,Phase 1
34 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
35 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
36 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
37 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
38 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
39 Antidotes Phase 3,Phase 2,Phase 1
40 Protective Agents Phase 3,Phase 2,Phase 1
41 Hormones Phase 2, Phase 3
42 Antibodies Phase 3,Phase 2,Phase 1,Early Phase 1
43 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1,Early Phase 1
44 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
45 Immunoglobulin G Phase 3,Phase 2,Phase 1
46 Immunoglobulins Phase 3,Phase 2,Phase 1,Early Phase 1
47 Mitogens Phase 3,Phase 2,Phase 1
48 Liver Extracts Phase 3,Phase 2,Phase 1,Early Phase 1
49 Antimetabolites Phase 3,Phase 2,Phase 1
50 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 185)
id Name Status NCT ID Phase
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3
2 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3
3 Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer Completed NCT00003749 Phase 3
4 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer Completed NCT00005583 Phase 3
5 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3
6 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3
7 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3
8 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3
9 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3
10 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3
11 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3
12 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704 Phase 3
13 Edrecolomab in Treating Patients With Stage II Colon Cancer Completed NCT00002968 Phase 3
14 Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer Completed NCT00005036 Phase 3
15 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Recruiting NCT02101788 Phase 2, Phase 3
16 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3
17 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
18 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT00565851 Phase 3
19 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02502266 Phase 2, Phase 3
20 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Recruiting NCT02065687 Phase 2, Phase 3
21 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3
22 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3
23 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3
24 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3
25 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3
26 Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Active, not recruiting NCT01672892 Phase 3
27 Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Active, not recruiting NCT01081262 Phase 3
28 Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer Active, not recruiting NCT00217737 Phase 3
29 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Not yet recruiting NCT02839707 Phase 2, Phase 3
30 Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer Terminated NCT00003880 Phase 2, Phase 3
31 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer Terminated NCT00002819 Phase 3
32 Comparison of Adjuvant Chemotherapy Regimens in Treating Patients With Stage II or Stage III Rectal Cancer Who Are Receiving Radiation Therapy and Fluorouracil Before or After Surgery Terminated NCT00068692 Phase 3
33 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
34 Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer Unknown status NCT02112552 Phase 2
35 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2
36 Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Unknown status NCT00003560 Phase 2
37 Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma Completed NCT00506779 Phase 1, Phase 2
38 Papillary Serous Carcinoma of the Endometrium Completed NCT00515073 Phase 2
39 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2
40 Phase II ABT-888 With Cyclophosphamide Completed NCT01306032 Phase 2
41 Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer Completed NCT00022620 Phase 2
42 Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer Completed NCT01583322 Phase 2
43 Uterine Papillary Serous Cancer (UPSC) Trial Completed NCT00147680 Phase 2
44 Toremifene in Treating Patients With Ovarian Cancer Completed NCT00003865 Phase 2
45 A Phase II Trial of Adjuvant Radiation Therapy With Ifosfamide in Patients With MMT of the Uterus Completed NCT00231842 Phase 2
46 AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00275028 Phase 2
47 Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01132820 Phase 2
48 Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00025467 Phase 2
49 Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer Completed NCT00052312 Phase 2
50 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01225887 Phase 2

Search NIH Clinical Center for Serous Cystadenocarcinoma

Cochrane evidence based reviews: cystadenocarcinoma, serous

Genetic Tests for Serous Cystadenocarcinoma

Anatomical Context for Serous Cystadenocarcinoma

MalaCards organs/tissues related to Serous Cystadenocarcinoma:

39
Ovary, Pancreas, Liver, Colon, Breast, Lymph Node, Testis

Publications for Serous Cystadenocarcinoma

Articles related to Serous Cystadenocarcinoma:

(show top 50) (show all 102)
id Title Authors Year
1
Estimation of Prognostic Marker Genes by Public Microarray Data in Patients with Ovarian Serous Cystadenocarcinoma. ( 27189279 )
2016
2
Serous Cystadenocarcinoma of the Pancreas: Clinical Features and Management of a Rare Tumor. ( 26998825 )
2016
3
Serous Cystadenocarcinoma Arising in Presumed Vitelline Duct Remnant: A Case Report and Implications in the Management of Cancer of Unknown Primary. ( 27999702 )
2016
4
DNA methylation-regulated microRNA pathways in ovarian serous cystadenocarcinoma: A meta-analysis. ( 27746113 )
2016
5
Single nucleotide polymorphisms in glutathione S-transferase P1 and M1 genes and overall survival of patients with ovarian serous cystadenocarcinoma treated with chemotherapy. ( 27073511 )
2016
6
A Five-Gene Expression Signature Predicts Clinical Outcome of Ovarian Serous Cystadenocarcinoma. ( 27478834 )
2016
7
Synchronous resection of pancreatic serous cystadenocarcinoma and liver metastasis: First reported case and review of literature. ( 26463518 )
2015
8
"Sea anemone-like ciliated tumor cells" in a case of serous cystadenocarcinoma of the ovary. ( 26811576 )
2015
9
Long-term survival of serous cystadenocarcinoma of the pancreas with synchronous liver metastases after aggressive surgical resection. ( 26177796 )
2015
10
Primary Peritoneal Papillary Serous Cystadenocarcinoma - A Rare Malignancy. ( 26713835 )
2015
11
Solid variant type of serous cystadenocarcinoma of the pancreas: AA case report and review of the literature. ( 25716800 )
2015
12
Serous cystadenocarcinoma of the mesentery in a man: case report and review of literature. ( 24759353 )
2014
13
Neoplasms in the trocar site and peritoneal papillary serous cystadenocarcinoma. ( 25017255 )
2014
14
Paratesticular papillary serous cystadenocarcinoma: A rare entity in Indian population. ( 25308020 )
2014
15
Ovarian serous cystadenocarcinoma metastasising to the breast. ( 23445161 )
2013
16
Histological percutaneous diagnosis of stage IV microcystic serous cystadenocarcinoma of the pancreas. ( 23370947 )
2013
17
IL-17A is elevated in sera of patients with poorly differentiated ovarian papillary serous cystadenocarcinoma. ( 24595078 )
2013
18
Serous cystadenocarcinoma of pancreas. ( 23763806 )
2013
19
Peritoneal papillary serous cystadenocarcinoma at a previous laparoscopic trocar site. ( 23040941 )
2012
20
Serous cystadenocarcinoma of the pancreas: report of a case and management reflections. ( 22400805 )
2012
21
Pancreatic serous cystadenocarcinoma with invasive growth into the colon and spleen. ( 22066125 )
2011
22
Imaging of pancreatic serous cystadenocarcinoma. ( 22009426 )
2011
23
Testicular papillary serous cystadenocarcinoma: a rare case report and review of the literature. ( 22355499 )
2011
24
Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade. ( 21266826 )
2010
25
Serous cystadenocarcinoma of the pancreas with portal thrombosis. ( 20499029 )
2010
26
Papillary serous cystadenocarcinoma of the stomach, peritoneum and ovary. ( 20163045 )
2009
27
Serous cystadenocarcinoma of the ovary in an 11-year-old girl with extensive dissemination and chylothorax: a case report and a brief review of literature. ( 19564753 )
2009
28
Pancreatic serous cystadenocarcinoma: a case report and review of the literature. ( 19459016 )
2009
29
Collision tumor: serous cystadenocarcinoma and dermoid cyst in the same ovary. ( 18818939 )
2009
30
Macrocystic serous cystadenocarcinoma of the pancreas: the first report of a new pattern of pancreatic carcinoma. ( 18305183 )
2008
31
Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma. ( 18574502 )
2008
32
Serous cystadenocarcinoma of the pancreas with metachronous hepatic metastasis. ( 19060596 )
2008
33
[Differential expression of USP2, USP14 and UBE4A between ovarian serous cystadenocarcinoma and adjacent normal tissues]. ( 17553343 )
2007
34
Plasma cell leukemia with ovarian serous cystadenocarcinoma. ( 17883177 )
2007
35
Immunohistochemical identification of primary peritoneal serous cystadenocarcinoma mimicking advanced colorectal carcinoma: a case report. ( 18036260 )
2007
36
Paratesticular papillary serous cystadenocarcinoma--a case report. ( 16625973 )
2006
37
[Oncogene ZNF217 amplification on chromosome 20 q in ovarian serous cystadenocarcinoma and its clinical implications]. ( 16793610 )
2006
38
[ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization]. ( 17160949 )
2006
39
Clinical significance of p21(WAF1/CIP1) and p53 expression in serous cystadenocarcinoma of the ovary. ( 16012716 )
2005
40
Serous cystadenocarcinoma of the pancreas: management of a rare entity. ( 16025006 )
2005
41
Primary papillary serous cystadenocarcinoma of broad ligament. ( 15845057 )
2005
42
Serous cystadenocarcinoma of the pancreas. ( 15982220 )
2005
43
A primary retroperitoneal serous cystadenocarcinoma with clinically aggressive behavior. ( 14551796 )
2004
44
Mean nuclear volume in ovarian papillary serous cystadenocarcinoma. ( 15032078 )
2004
45
Plasma cell leukaemia with papillary serous cystadenocarcinoma of ovary--a case report. ( 15025299 )
2003
46
Hepatic resection of metastatic tumor from serous cystadenocarcinoma of the ovary. ( 12068151 )
2002
47
Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. ( 11201519 )
2001
48
Immunohistochemical localization of aromatase and apoptosis-associated proteins in ovarian serous cystadenocarcinoma arising from ovarian endometriosis. ( 11516810 )
2001
49
Borderline serous cystadenocarcinoma with coexistent angiosarcoma: an unusual form of ovarian carcinosarcoma. ( 12574850 )
2001
50
Successful treatment of an advanced ovarian serous cystadenocarcinoma in pregnancy with cisplatin, adriamycin and cyclophosphamide (CAP) regimen. Case report. ( 10968352 )
2000

Variations for Serous Cystadenocarcinoma

Expression for Serous Cystadenocarcinoma

Search GEO for disease gene expression data for Serous Cystadenocarcinoma.

Pathways for Serous Cystadenocarcinoma

Pathways related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.79 AKT1 BAX BIRC5 CDKN1A ESR2 PGR
2
Show member pathways
13.7 AKT1 BCL2 BIRC5 CDKN1A ESR2 MMP2
3
Show member pathways
13.35 AKT1 BCL2 BIRC5 CDKN1A MMP2 TP53
4
Show member pathways
12.98 AKT1 BAX BIRC5 CDKN1A TP53 USP2
5
Show member pathways
12.92 AKT1 BAX BCL2 BIRC5 CDKN1A TP53
6
Show member pathways
12.88 AKT1 BAX BCL2 CDKN1A ESR2 MMP2
7
Show member pathways
12.83 AKT1 BAX BCL2 BIRC5 CDKN1A TP53
8
Show member pathways
12.8 AKT1 BAX BCL2 TP53 VEGFA
9 12.61 AKT1 BCL2 CDKN1A TP53 VEGFA
10
Show member pathways
12.55 AKT1 BAX BCL2 BIRC5 CDKN1A MMP2
11 12.51 BCL2 CDKN1A TP53 VEGFA
12
Show member pathways
12.48 AKT1 BAX BCL2 ESR2
13 12.46 AKT1 BAX BCL2 BIRC5 CDKN1A MMP2
14
Show member pathways
12.44 AKT1 BAX BCL2 TP53
15 12.42 AKT1 BAX CDKN1A TP53
16
Show member pathways
12.4 AKT1 BAX BIRC5 CDKN1A TP53
17
Show member pathways
12.34 AKT1 BAX BCL2 BIRC5 CDKN1A TP53
18 12.32 AKT1 CDKN1A MMP2 TP53 VEGFA
19 12.31 AKT1 BCL2 CDKN1A TP53
20
Show member pathways
12.27 AKT1 BAX BCL2 CDKN1A TP53
21 12.17 AKT1 BAX BCL2 TP53 VEGFA
22 12.13 AKT1 BAX BCL2 CDKN1A TP53
23
Show member pathways
12.12 AKT1 CDKN1A TP53 VEGFA
24 12.11 AKT1 BCL2 MMP2 TP53 VEGFA
25 12.08 BAX BCL2 CDKN1A MMP2 TP53
26 12.06 AKT1 BAX BCL2 CDKN1A TP53 USP2
27
Show member pathways
12.05 AKT1 BAX BCL2 TP53
28 12.03 AKT1 BAX BCL2 TP53
29
Show member pathways
12.01 AKT1 BAX BCL2
30 11.99 AKT1 BAX BCL2 CDKN1A TP53
31
Show member pathways
11.97 BAX BCL2 TP53
32 11.96 AKT1 CDKN1A TP53
33 11.94 BCL2 CDKN1A TP53
34
Show member pathways
11.94 BAX BIRC5 TP53
35 11.93 AKT1 BCL2 CDKN1A VEGFA
36
Show member pathways
11.92 BAX CDKN1A TP53
37 11.92 AKT1 BAX BCL2 MMP2 VEGFA
38 11.92 AKT1 BAX BIRC5 CDKN1A MMP2 TP53
39 11.83 AKT1 BAX CDKN1A TP53
40
Show member pathways
11.82 BAX BCL2 BIRC5
41 11.82 AKT1 BCL2 TP53
42 11.8 BAX BIRC5 TP53
43 11.77 CDKN1A MMP2 TP53 VEGFA
44
Show member pathways
11.75 AKT1 TP53 USP2
45 11.72 BCL2 CDKN1A MMP2 TP53 VEGFA
46
Show member pathways
11.68 BIRC5 MMP2 VEGFA
47 11.63 AKT1 CDKN1A VEGFA
49 11.54 AKT1 BIRC5 CDKN1A TP53 VEGFA
50 11.51 AKT1 BAX BCL2

GO Terms for Serous Cystadenocarcinoma

Cellular components related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 mitochondrion GO:0005739 9.7 AKT1 BAX BCL2 ESR2 MMP2 PGR
2 nucleoplasm GO:0005654 9.61 AKT1 BCL2 BIRC5 CDKN1A ESR2 PGR
3 pore complex GO:0046930 8.62 BAX BCL2
4 nucleus GO:0005634 10.03 AKT1 BAX BCL2 BIRC5 CDKN1A ESR2

Biological processes related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show all 32)
id Name GO ID Score Top Affiliating Genes
1 cellular response to DNA damage stimulus GO:0006974 9.92 AKT1 BAX BCL2 CDKN1A TP53
2 regulation of apoptotic process GO:0042981 9.88 BAX BCL2 BIRC5 TP53
3 regulation of cell cycle GO:0051726 9.83 BAX BCL2 CDKN1A
4 kidney development GO:0001822 9.8 BAX BCL2 VEGFA
5 response to toxic substance GO:0009636 9.79 BAX BCL2 CDKN1A
6 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.76 AKT1 BCL2 VEGFA
7 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.71 BAX CDKN1A TP53
8 negative regulation of cell growth GO:0030308 9.67 BCL2 CDKN1A ESR2 TP53
9 entrainment of circadian clock by photoperiod GO:0043153 9.65 TP53 USP2
10 negative regulation of apoptotic signaling pathway GO:2001234 9.65 BAX BCL2
11 ovarian follicle development GO:0001541 9.65 BAX BCL2 VEGFA
12 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.63 CDKN1A TP53
13 endoplasmic reticulum calcium ion homeostasis GO:0032469 9.63 BAX BCL2
14 response to gamma radiation GO:0010332 9.63 BAX BCL2 TP53
15 positive regulation of protein oligomerization GO:0032461 9.62 BAX TP53
16 growth GO:0040007 9.61 BCL2 VEGFA
17 positive regulation of intrinsic apoptotic signaling pathway GO:2001244 9.61 BAX BCL2 TP53
18 replicative senescence GO:0090399 9.6 CDKN1A TP53
19 regulation of mitochondrial membrane permeability GO:0046902 9.59 BCL2 TP53
20 intrinsic apoptotic signaling pathway GO:0097193 9.58 BAX CDKN1A TP53
21 regulation of protein heterodimerization activity GO:0043497 9.57 BAX BCL2
22 regulation of protein homodimerization activity GO:0043496 9.56 BAX BCL2
23 circadian behavior GO:0048512 9.55 TP53 USP2
24 signal transduction by p53 class mediator GO:0072331 9.51 CDKN1A TP53
25 leukocyte homeostasis GO:0001776 9.49 BAX BCL2
26 cellular response to hypoxia GO:0071456 9.46 AKT1 BCL2 TP53 VEGFA
27 negative regulation of apoptotic process GO:0043066 9.43 AKT1 BCL2 BIRC5 CDKN1A TP53 VEGFA
28 regulation of nitrogen utilization GO:0006808 9.32 BAX BCL2
29 positive regulation of developmental pigmentation GO:0048087 9.26 BAX BCL2
30 apoptotic mitochondrial changes GO:0008637 8.8 AKT1 BAX BCL2
31 negative regulation of transcription from RNA polymerase II promoter GO:0000122 10.04 ESR2 TP53 USP2 VEGFA ZNF217
32 apoptotic process GO:0006915 10.04 AKT1 BAX BCL2 BIRC5 TP53

Molecular functions related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 ubiquitin protein ligase binding GO:0031625 9.73 BCL2 CDKN1A TP53 USP2
2 enzyme binding GO:0019899 9.65 AKT1 BIRC5 ESR2 PGR TP53
3 chaperone binding GO:0051087 9.54 BAX BIRC5 TP53
4 channel activity GO:0015267 9.4 BAX BCL2
5 BH3 domain binding GO:0051434 9.32 BAX BCL2
6 identical protein binding GO:0042802 9.17 AKT1 BAX BCL2 BIRC5 TP53 USP2
7 protein phosphatase 2A binding GO:0051721 9.13 AKT1 BCL2 TP53
8 protein binding GO:0005515 10.03 AKT1 ALPP BAX BCL2 BIRC5 CDKN1A

Sources for Serous Cystadenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....